skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin

Journal Article · · Molecular Cancer Therapeutics
 [1];  [2];  [3];  [4];  [2];  [5];  [5];  [2];  [2];  [6];  [6];  [2];  [7];  [5];  [8];  [9];  [10]
  1. Univ. of California Davis, Sacramento, CA (United States). Dept. of Internal Medicine. School of Medicine; Fourth Military Medical Univ., Xi'an (China). Dept. of Urology. Xijing Hospital
  2. Univ. of California Davis, Sacramento, CA (United States). Dept. of Internal Medicine. School of Medicine
  3. Univ. of California Davis, Sacramento, CA (United States). Dept. of Biochemistry and Molecular Medicine. School of Medicine
  4. Univ. of California Davis, Sacramento, CA (United States). Dept. of Internal Medicine. School of Medicine; Wuhan Univ. (China). Dept. of Urology. Renmin Hospital
  5. Univ. of California, Davis, CA (United States). Dept. of Entomology and Nematology
  6. Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
  7. The Jackson Lab., Bar Harbor, ME (United States)
  8. Fourth Military Medical Univ., Xi'an (China). Dept. of Urology. Xijing Hospital
  9. Univ. of California Davis, Sacramento, CA (United States). Dept. of Urology. School of Medicine. Comprehensive Cancer Center
  10. Univ. of California Davis, Sacramento, CA (United States). Dept. of Internal Medicine. Dept. of Urology. School of Medicine. Comprehensive Cancer Center; VA Northern California Health Care System, Rancho Cordova, CA (United States)
+ Show Author Affiliations

Cisplatin-based therapy is highly toxic, but moderately effective in most cancers. Concurrent inhibition of cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH) results in antitumor activity and has organ-protective effects. The goal of this paper was to determine the antitumor activity of PTUPB, an orally bioavailable COX-2/sEH dual inhibitor, in combination with cisplatin and gemcitabine (GC) therapy. NSG mice bearing bladder cancer patient-derived xenografts were treated with vehicle, PTUPB, cisplatin, GC, or combinations thereof. Mouse experiments were performed with two different PDX models. PTUPB potentiated cisplatin and GC therapy, resulting in significantly reduced tumor growth and prolonged survival. PTUPB plus cisplatin was no more toxic than cisplatin single-agent treatment as assessed by body weight, histochemical staining of major organs, blood counts, and chemistry. The combination of PTUPB and cisplatin increased apoptosis and decreased phosphorylation in the MAPK/ERK and PI3K/AKT/mTOR pathways compared with controls. PTUPB treatment did not alter platinum–DNA adduct levels, which is the most critical step in platinum-induced cell death. The in vitro study using the combination index method showed modest synergy between PTUPB and platinum agents only in 5637 cell line among several cell lines examined. However, PTUPB is very active in vivo by inhibiting angiogenesis. Finally, PTUPB potentiated the antitumor activity of cisplatin-based treatment without increasing toxicity in vivo and has potential for further development as a combination chemotherapy partner.

Research Organization:
Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States); Univ. of California Davis, Sacramento, CA (United States)
Sponsoring Organization:
USDOE; Dept. of Veterans Affairs (VA) (United States); National Inst. of Health (NIH) (United States)
Grant/Contract Number:
AC52-07NA27344; I01 BX001784; 2 P30 CA 0933730; R01 ES002710; P42 ES04699; HHSN261201200048C; R01 DK103616; U54 NS079202
OSTI ID:
1438685
Report Number(s):
LLNL-JRNL-741222
Journal Information:
Molecular Cancer Therapeutics, Vol. 17, Issue 2; ISSN 1535-7163
Publisher:
American Association for Cancer Research (AACR)Copyright Statement
Country of Publication:
United States
Language:
English
Citation Metrics:
Cited by: 23 works
Citation information provided by
Web of Science

Cited By (5)

Cyclooxygenase-2 in cancer: A review: HASHEMI et al. journal October 2018
Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor journal January 2019
COX‐2/sEH dual inhibitor PTUPB alleviates bleomycin‐induced pulmonary fibrosis in mice via inhibiting senescence journal November 2019
Curbing Lipids: Impacts ON Cancer and Viral Infection journal February 2019
Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science journal May 2019

Figures / Tables (12)

Figure 1:(p. 30)figure Figure 1:
Figure 2:(p. 31)figure Figure 2:
Figure 3:(p. 32)figure Figure 3:
Figure 4:(p. 33)figure Figure 4:
Figure 5:(p. 34)figure Figure 5:
Table 1.(p. 35)table Table 1.
Figure S1.(p. 36)figure Figure S1.
Figure S2.(p. 37)figure Figure S2.
Figure S3.(p. 38)figure Figure S3.
Figure S4.(p. 39)figure Figure S4.
Figure S6.(p. 41)figure Figure S6.
Figure S5.(p. 41)figure Figure S5.

Similar Records

DN604: A platinum(II) drug candidate with classic SAR can induce apoptosis via suppressing CK2-mediated p-cdc25C subcellular localization in cancer cells
Journal Article · Thu Mar 15 00:00:00 EDT 2018 · Experimental Cell Research · OSTI ID:1438685
+1 more
Downregulation of COX-2 and CYP 4A signaling by isoliquiritigenin inhibits human breast cancer metastasis through preventing anoikis resistance, migration and invasion
Journal Article · Wed Oct 01 00:00:00 EDT 2014 · Toxicology and Applied Pharmacology · OSTI ID:1438685
+6 more
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma
Journal Article · Wed Feb 01 00:00:00 EST 2006 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:1438685
+4 more

Related Subjects

60 APPLIED LIFE SCIENCES